BioSyent Inc. (CVE:RX – Get Free Report) Director Seyed Ahmad Ashrafi sold 1,884 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of C$14.65, for a total value of C$27,600.60. Following the completion of the sale, the director directly owned 37,261 shares of the company’s stock, valued at approximately C$545,873.65. This trade represents a 4.81% decrease in their position.
Seyed Ahmad Ashrafi also recently made the following trade(s):
- On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 800 shares of BioSyent stock. The shares were sold at an average price of C$14.70, for a total value of C$11,760.00.
- On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 600 shares of BioSyent stock. The stock was sold at an average price of C$14.50, for a total transaction of C$8,700.00.
BioSyent Trading Down 0.8%
Shares of CVE RX traded down C$0.12 during mid-day trading on Friday, hitting C$14.60. The stock had a trading volume of 4,970 shares, compared to its average volume of 6,645. The company has a debt-to-equity ratio of 11.66, a quick ratio of 6.91 and a current ratio of 1.89. BioSyent Inc. has a 1 year low of C$10.65 and a 1 year high of C$15.80. The business has a 50 day moving average price of C$14.20 and a two-hundred day moving average price of C$14.22. The firm has a market cap of C$165.45 million, a P/E ratio of 18.62 and a beta of 0.99.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Further Reading
- Five stocks we like better than BioSyent
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
